Bridgefront Capital, LLC Tcr2 Therapeutics Inc. Transaction History

Bridgefront Capital, LLC

  • $249 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 12, 2021
SELL
$16.41 - $24.71 $148,822 - $224,094
-9,069 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$20.38 - $34.07 $184,826 - $308,980
9,069 New
9,069 $200,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Bridgefront Capital, LLC Portfolio

Follow Bridgefront Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgefront Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email